

Title: Anti Hepatitis C viral drugs Remdesivir and Uprifosbuvir derivatives are better inhibitors of SARS Cov2 RNA-dependent RNA polymerase determined by docking studies.

Gudipati Pavan Kumar¹, Shyamasri Biswas², Pankaj Goyal³

1. Gudipati Pavan Kumar¹, Pragathi Nagar, Hyderabad, India, 500090 Email: gpavankumar1974@gmail.com
2. Shyamasri Biswas², ²USA Prime Biotech LLC, Gainesville, FL-32608.
3. Pankaj Goyal³, Department of Biotechnology, School of Life Sciences, Central University of Rajasthan, Bandarsindri, Kishangarh, Rajasthan 305817 India.

*To whom correspondence may be addressed:

GPK : gpavankumar1974@gmail.com

Abstract: SARS Cov2 RNA-dependent RNA polymerase (RdRp) is an enzyme that catalyzes the synthesis and replication of viral RNA from an RNA template. Our starting model for this study was (SARS-Cov-2) cryo-EM structure published recently (pdb ID 6m71). We have used docking studies to find a better inhibitor for the enzyme that can be used in the treatment of SARS-CoV2 infections. Recently, several inhibitors like Sofosbuvir, Ribavirin, and Remdesivir has been reported as strong inhibitors of this enzyme. Our results show an analogue of Remdesivir such as CHEMBL3120791 and analogue of Uprifosbuvir SCHEMBL20762917, SCHEMBL20733228 as better inhibitors than previously reported inhibitors of RNA-dependent RNA polymerase. Using Autodock Vina and Pyrx software for virtual screening of ligands, we found four higher efficiency compounds CHEMBL3120791, SCHEMBL20762917 SCHEMBL20733228, and Uprifosbuvir. The binding constant of these ligands were -9.5 (Kcal/mol), -8.3 (Kcal/mol), -8.3 (Kcal/mol), -8.6 (Kcal/mol), respectively when tested on SARS-COV-2 nsp12. Active site interactions with the potential drug molecule are with residues Lys47, Tyr129, Ser784, His133, Ser709 for CHEMBL3120791, SCHEMBL20762917 SCHEMBL20733228. These molecules can be used in the future drug development process in the treatment of SARS-Cov2 infection. The molecules reported here are already under clinical trial for the treatment of HCV (Hepatitis C Virus) infections, which is similar to SARS Cov2, as both are positive-sense RNA Viruses.

Keywords: SARS Cov2, RNA-dependent RNA polymerase, RdRP, Docking, Drug Design, Hepatitis C Virus, Remdesivir, Uprifosbuvir, CHEMBL3120791, SCHEMBL20762917 SCHEMBL20733228

Introduction:

SARS CoV-2 virus that causes COVID-19 respiratory disease has emerged as one of the deadly pathogens of the 21st century¹. SARS CoV2 is an enveloped non segmented positive sense RNA coronavirus belonging to genus *Betacoronavirus*². This genus also includes two other RNA viruses that has caused epidemics like Severe Acute Respiratory Syndrome (SARS) caused by SARS-CoV and Middle East Respiratory Syndrome (MERS) caused by MERS-CoV^{3,4}. Due to high affinity of the viral spike protein with host receptor, infection of SARS CoV-2 is known to increase exponentially thereby increasing human to human transmission⁵.

RNA dependent RNA polymerase (RdRp) of SARS COV-2 is known to mediate replication of the viral genome and its propagation inside host cells⁶. The core component of RdRP is nsp12 (non structured protein) which has little activity but together with nsp7 and nsp8 can increase RdRP template binding and processivity rate^{7,8}. RdRP is also the target of a class of antivirals like Remdesivir⁹ that has come into spotlight recently as human clinical trials have shown promise in treatment of COVID-19. Remdesivir is a nucleotide analog and is a prodrug that is converted to active drug in triphosphate form inside cells^{10,11}.

Angiotensin converting enzyme (ACE2) receptor has been identified as the entry point for SARS virus into host cells¹². ACE2 is expressed in various organs and tissues namely lungs, cardiovascular system, gut, kidneys, central nervous system, and adipose tissue¹³. The spike protein of SARS virus has strong binding affinity for the ACE2 receptor. Although SARS CoV-2 receptor binding domain has close homology to most SARS virus, there are several amino acids that are different¹⁴. These differences in amino acid composition allow SARS CoV2 to bind to ACE2 with higher affinity thereby spreading the disease and enabling viral replication¹⁵.

Apart from ACE2 receptor and SARS CoV2 RdRp, coronavirus main proteinase (3CL^{pro}) has also been reported as a potential drug target against SARS virus^{16,17,18}. This proteinase is a major component of coronavirus replication complex and belongs to the cysteine protease family, it also plays a major role in processing polyproteins¹⁹. Inhibition of this proteinase function will hamper replication and proliferation of the virus²⁰.

In this report we have used docking studies with Remdesivir as well as its *analogues* and Ribavirin, Uprifosbuvir, Adafosbuvir and several other compounds to find the best inhibitor for RdRp. We identified a few compounds that had better efficacy not only towards RdRp but also can be used for inhibition of SARS main proteinase 3CL^{pro} and SARS CoV2 spike glycoprotein. Thus the inhibitors identified in this docking study can be used as a broad spectrum inhibitor for number of target proteins present in SARS CoV2. We believe these results will enable us to design better drugs for the treatment of this deadly virus.

Material & Methods

Protein File: In this study, the structure of SARS CoV-2 RdRp (RNA-dependent RNA polymerase) was used as a starting model (PDB ID 6m71^{21,22}). The structure was obtained from the RCSB website with pdb ID 6m71. This is a 2.9Å resolution cryo EM structure consisting of 4 chains, which are A, B, C and D. In this structure A Chain is the SARS-Cov2 nsp12, B, D chains are SARS-Cov2 nsp8 and C Chain is

SARS-CoV-2 nsp7. Recent reports by Kirchdoerfer, R.N., Ward et.al indicates that all three non-structured proteins are assembled to form the RdRp enzyme²³.

Chemical Data: The data for the inhibitors were collected from Pubchem²⁴ which includes various antiviral drugs such as Ribavirin, Uprifosbuvir, Remdesivir, Adafosbuvir, and their analogs. Remdesivir is a potential inhibitor for SARS-Cov-2 RNA-dependent RNA polymerase. Remdesivir interacts with active site residues Arg-555, Ser-549 and Asp-618 of this RdRP protein¹⁷. Ribavirin is a synthetic nucleoside analog of ribofuranose with activity against hepatitis C virus and other RNA viruses^{25, 26}, Uprifosbuvir is under investigation in clinical trial for Hepatitis C Virus (HCV)²⁷, Adafosbuvir also exhibits antiviral activity²⁸. In order to find a better inhibitor that binds RdRp with better binding efficiency than Remdesivir, we selected thirty one compounds in our docking studies.

The list of compounds used for this study are as follows: Ribavirin and their analogues, CID 5064 (ICN 1229), CID 37542 (Ribavirin), CID 100252 (Ribavirin monophosphate), CID 122108 (Ribavirin 5'-triphosphate), CID 124970 (Ribavirin 5'-diphosphate), CID 129235 (Ribavirin 5'-sulfamate), CID 362949 (SCHEMBL6981526), CID 451448 (Ribavirin amidine), CID 451949 (dd-ribavarin), CID 452722 (3'-Deoxyribavirin), CID 460516 (L-Ribavirin), CID 6713992 (Ribavirin E), CID 10220469 (SCHEMBL1981630), CID 11436477 (alpha-Ribavirin), CID 40629571 (SCHEMBL326516), CID 54759694 (CHEMBL3120793), CID 70989848 (SCHEMBL13761348), and other than Ribavirin, such as CID 90055716 (Uprifosbuvir), CID 76325303 (CHEMBL3120791), CID 118596336 (Adafosbuvir), CID 121304016 (Remdesivir), CID 137465280 (SCHEMBL20705434), CID 137490591 (SCHEMBL20733226), CID 137490593 (SCHEMBL20733228), CID 137509756 (SCHEMBL20754604), CID 137517260 (SCHEMBL20762917), CID 137517361 (SCHEMBL20763026), CID 45375808 (Sofosbuvir), CID 6440764 (Thymectacin), CID 3652 (hydroxychloroquine), CID 71826 (Cletoquine). Total of 31 molecules were selected for docking studies. (Supplemental -Table 1)

Docking Studies: We performed docking studies using two different strategies, first we excluded B, C and D chains and used only "A" chain for docking and in the second iteration we used all 4 chains which is the complete enzyme complex. Recent reports indicate that nsp12(chain A) has low template binding and processivity rate by itself, for efficient binding and activity the whole enzyme complex with chain A, B, C & D are required^{7,8}. Hence, we also performed docking studies with the whole enzyme complex comprising of nsp12, nsp7 and nsp8. For Docking, we used Autodock²⁹, Autodock Vina³⁰ and PyRx³¹. Apart from selective Ligands, we have used control, which are Sugar, Amino Sugar, and maltose.

In order to investigate whether these inhibitors can also work with spike protein inhibition of SARS-CoV2 we downloaded pdb file for spike protein of SARS-CoV2. The pdb file used for this was 2GHV³², which is receptor binding domain of SARS spike protein. We also performed docking studies using 5XLR (SARS-CoV2 spike glycoprotein)³³, 1P9U (Corona virus main proteinase 3CLpro)²⁰.

Results and Discussion:

In this report we have performed docking studies with 31 different molecules that are Remdesivir analogues (Supplemental Table - 1). We have used Autodock, Autodock Vina, and PyRx virtual screening software. Our starting pdb was 6m71 which is RNA dependent RNA polymerase of SARS CoV-2. Out of 31 compounds used for our docking studies we identified four compounds that produced better binding efficiency than Remdesivir particularly with chain A or nsp12 molecule

alone. These compounds are CID 76325303 (CHEMBL3120791), CID 137490593 (SCHEMBL20733228), CID 90055716 (Uprifosbuvir) and CID 137517260 (SCHEMBL20762917).

Our Rational behind using CID 76325303 (CHEMBL3120791) and CID 137490593 (SCHEMBL20733228) originates from the fact that these two compounds has been reported to exhibit antiviral activity against HCV (Hepatitis C Virus) genotype 1b ³⁴. In this study, human HuH7 cells were used and when treated with these compounds the viral replication was inhibited after 3 days studied by luminescence assay. Previous studies have shown CID 137490593 (SCHEMBL20733228) and CID 90055716 (Uprifosbuvir) exhibited antiviral activity against HCV infections ^{27, 35}. Most of these drugs are under clinical trials.

In our docking studies with chain A (SARS-COV-2 nsp12) better binding affinity was observed with four compounds identified as CID 76325303 (CHEMBL3120791), CID 137490593 (SCHEMBL20733228), CID 90055716 (Uprifosbuvir) and CID 137517260 (SCHEMBL20762917) (Fig2). The respective binding energy for these compounds were: CID 76325303 (CHEMBL3120791) -9.5 Kcal/mol, CID 137490593 (SCHEMBL20733228) : -8.3 Kcal/mol, CID 90055716 (Uprifosbuvir) -8.6 Kcal/mol and CID 137517260 (SCHEMBL20762917) with -8.3 Kcal/mol. Remdesivir in comparison had much lower binding energy of -6.8 kcal/mol (Table 2)

Table2: Binding Energy of ligands on "A" Chain SARS-COV-2 nsp12 Only. Controls: Sugar -6.8, Maltose -6.8 and Amino sugar with -5.6 Kcal/mol. Note: Docking Area for autodock vina [center_x = 120.0512, center_y = 116.143422415, center_z = 120.1478, size_x = 40.9508026378, size_y = 25.5156474687, size_z = 40.9508026378] in config file.

Ligand (Pubchem Id)	Binding Energy (Kcal/mol)	Chemical Name
CID 76325303	-9.5	CHEMBL3120791
CID 137490593	-8.3	SCHEMBL20733228
CID 90055716	-8.6	Uprifosbuvir
CID 137517260	-8.3	SCHEMBL20762917
CID 45375808	-8.0	Sofosbuvir
CID 137509756	-8.3	SCHEMBL20754604
CID 137517361	-8.8	SCHEMBL20763026
CID 121304016	-6.8	Remdesivir

Docking results with all four chains which include nsp12, nsp7 and nsp8, yielded the following binding energies: CID 90055716 (Uprifosbuvir): -8.8 Kcal/mol, CID 76325303(CHEMBL3120791): -8.5 Kcal/mol, CID 137517260 (SCHEMBL20762917): -8.3 Kcal/mol. The binding energy with Remdesivir is -8.2 kcal/mol, which is close to the compound studied here. The active site residues that interact with Remdesivir are Ser549, Arg555 and Asp618 all located in Chain A or nsp12. (Table 3)

Table 3: Binding Energy of ligands after Autodock Vina using PyRx on All Chains, which Includes nsp12, nsp8, nsp7. Controls: Sugar -6.8, Maltose -6.3 and Amino sugar with -5.4 Kcal/mol

Pubchem Id	Binding Energy (Kcal/mol)	Chemical Name
CID 90055716	-8.8	Uprifosbuvir
CID 76325303	-8.5	CHEMBL3120791
CID 137517260	-8.3	SCHEMBL20762917
CID 121304016	-8.2	Remdesivir
CID 45375808	-7.8	Sofosbuvir
CID 137490591	-7.7	SCHEMBL20733226
CID 137490593	-7.7	SCHEMBL20733228
CID 137509756	-7.7	SCHEMBL20754604
CID 118596336	-7.6	Adafosbuvir

From our docking studies with CID 76325303 the interacting residues identified were Lys47, Ser784, Tyr129, His133, Thr141 using Ligplus+

Fig1: CHEMBL3120791 (CID 76325303) with 6M71 using LigPlus+




Table 4: Using LigPlus+, the active site amino acids for these Ligand Molecule on Chain A –nsp12

	Ligands	Active Site – Amino Acids
1	CHEMBL3120791 (CID 76325303)	Lys47,Ser784,Tyr129, His133
2	SCHEMBL20733228 (CID 137490593)	Lys 47, Ser709, Thr141, His133
3	SCHEMBL20762917 (CID 137517260)	Lys47,Ser784,Tyr129, His133, Ser709,Asn781
4.	CID 90055716 (Uprifosbuvir)	Lys47,His133,Tyr129,Ser709, Thr141

CID 76325303 (CHEMBL3120791) is Remdesivir analogue, where as CID 137490593 (SCHEMBL20733228), and CID 137517260 (SCHEMBL20762917) are CID 90055716 (Uprifosbuvir) analogue. They are potential inhibitors, and have previously shown antiviral activity in wet lab analysis in case of HCV virus²⁷. We believe efficacy of these potential inhibitors can be tested against SARS Coronavirus 2 – RdRP. The conformational stability of this molecule can be tested using Molecular Dynamic simulation. Further experimental data in wetlab will provide evidence of the efficacy of these molecules. (Fig 2.1 to Fig 2.5)

Fig2: Structural Difference of high binding Energy Molecules with Remdesivir analogue and Uprifosbuvir analogue. Note: Arrow is direction, where molecules have a difference with each other. Fig 2.1 to Fig 2.5

A) Remdesivir and CHEMBL3120791




Fig 2.1 Remdesivir (CID_121304016)






Fig. 2.2 CHEMBL3120791 (CID_76325303)


B) Uprifosbuvir Analogues



SCHEMBL20733228
(CID_137490593)
Fig 2.3



Uprifosbuvir
(CID_90055716)
Fig 2.4



SCHEMBL20762917
(CID_137517260)
Fig 2.5

The hepatitis C virus (HCV) is a small, enveloped, single-stranded, positive-sense RNA virus which is similar to Coronaviruses which have positive-sense, single-stranded RNA genome³⁸. The inhibitor identified in this study has been tested against HCV virus²⁷.

We also investigated binding efficacy of these identified inhibitors against SARS spike protein for this we used pdb files 2GHV (SARS spike protein receptor binding domain) and 5XLR (SARS CoV spike glycoprotein). In addition, 1P9U which is coronavirus main proteinase was also evaluated. The compounds identified and reported here also showed better binding affinity towards these proteins.

Table 5: Binding Energy with other than RNA dependent RNA polymerase: PDB Id's 2GHV, 5XLR, 1P9U. Binding Energy in (Kcal/mol).

	Ligand / Chemical	2GHV	5XLR	1P9U
1	CID 76325303 (CHEMBL3120791)	-7.4	-8.8	-9.5
2	CID 137490593 (SCHEMBL20733228)	-6.4	-8.5	-8.5
3	CID 137517260 (SCHEMBL20762917)	-7.0	-8.2	-8.8
5	CID 90055716 (Uprifosbuvir)	-6.9	-7.8	-8.5
5	CID 121304016 (Remdesivir)	-6.5	-2.8	-9.3

From these studies we can conclude that these inhibitors can be potentially used not only in the prevention of viral RNA replication but also against virus receptor binding reaction. If the spike protein is inhibited from binding human ACE2 receptor viral load can be decreased. The main proteinase of SARS virus also was inhibited with these compounds. The inhibitors identified here can be tested further in human clinical trials as they exhibit better binding than Remdesivir.

References:

1. W.H.O. 2020; WHO Coronavirus Disease (COVID-19) Dashboard, <https://covid19.who.int/>
2. Malik YA, Properties of Coronavirus and SARS-CoV-2., *Malays J Pathol.* 2020 Apr;42(1):3-11.
3. Colombia. Miranda J, Mattar S, Gonzalez M, Hoyos-López R, Aleman A, Aponte, First report of Culex flavivirus infection from Culex coronator (Diptera: Culicidae), *J irol J.* 2019 Jan 3;16(1):1.
4. van Regenmortel MHV, Fauquet CM, Bishop DHL, Carstens EB, Estes MK, Lemon SM, et al. Coronaviridae. In: MHV v R, Fauquet CM, DHL B, Carstens EB, Estes MK, Lemon SM, et al., editors. *Virus taxonomy: Classification and nomenclature of viruses Seventh report of the International Committee on Taxonomy of Viruses.* San Diego: Academic Press; 200: 835–49. ISBN 0123702003
5. Costa, Vivaldo & Moreli, Marcos & Saivish, Marielena. (2020). The emergence of SARS, MERS and novel SARS-2 coronaviruses in the 21st century. *Archives of Virology.* 10.1007/s00705-020-04628-0.
6. Venkataraman, Sangita & Burra, Prasad & SELVARAJAN, RAMASAMY. (2018). RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution. *Viruses.* 10. 76. 10.3390/v10020076.
7. Lovika Mittal, Anita Kumari, Charu Suri, Sankar Bhattacharya & Shailendra Asthana (2020) Insights into structural dynamics of allosteric binding sites in HCV RNA-dependent RNA polymerase, *Journal of Biomolecular Structure and Dynamics*, 38:6, 1612-1625, DOI: 10.1080/07391102.2019.1614480
8. Yin, Wanchao & Mao, Chunyou & Luan, Xiaodong & Shen, Dan-Dan & Shen, Qingya & Su, Haixia & Xiaoxi, Wang & Zhou, Fulai & Zhao, Wenfeng & Gao, Minqi & Chang, Shenghai & Xie, Yuan-Chao & Tian, Guanghui & Jiang, He-Wei & Tao, Sheng-Ce & Shen, Jingshan & Jiang, Yi & Jiang, H. & Xu, Yechun & Xu, Eric. (2020). Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir. *Science.* eabc1560. 10.1126/science.abc1560.
9. Zhang, L.; Zhou, R. Binding Mechanism of Remdesivir to SARS-CoV-2 RNA Dependent RNA Polymerase. *Preprints 2020*, 2020030267 (doi: 10.20944/preprints202003.0267.v1).
10. Eastman, Richard & Roth, Jacob & Brimacombe, Kyle & Simeonov, Anton & Shen, Min & Patnaik, Samarjit & Hall, Matthew. (2020). Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19. *ACS Central Science.* XXXX. 10.1021/acscentsci.0c00489.
11. Green N.; Ott R. D.; Isaacs R. J.; Fang H. Cell-based Assays to Identify Inhibitors of Viral Disease. *Expert Opin. Drug Discovery* 2008, 3, 671–676. 10.1517/17460441.3.6.671
12. Zhou, Peng & Yang, Xinglou & Wang, Xian-Guang & Hu, Ben & Zhang, Lei & Zhang, Wei & Si, Hao-Rui & Zhu, Yan & Li, Bei & Huang, Chao-Lin & Chen, Hui-Dong & Chen, Jing & Luo, Yun & Guo, Hua & Jiang, Ren-Di & Liu, Mei-Qin & Chen, Ying & Shen, Xu-Rui & Wang, Xi. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature.* 579. 10.1038/s41586-020-2012-7.
13. gheblawi, mahmoud & wang, kaiming & Viveiros, Anissa & Nguyen, Quynh & Zhong, Jiuchang & Turner, Anthony & Raizada, Mohan & Grant, Maria & Oudit, Gavin. (2020). Angiotensin Converting

Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System. *Circulation Research*. 10.1161/CIRCRESAHA.120.317015.

14. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, Graham BS, McLellan JS, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. *Science*. 2020 Mar 13; 367(6483):1260-1263.

15. Xu X., Chen P., Wang J., Feng J., Zhou H., Li X., Zhong W., Hao P. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. *Science China Life Sciences*. 2020;63(3):457–460.

16. Potential use of RNA-dependent RNA polymerase (RdRp) inhibitor against COVID-19 infection C Allen, S Arjona, M Santerre - 2020 , Book

17. Zhang, Leili & Zhou, Ruhong. (2020). Binding Mechanism of Remdesivir to SARS-CoV-2 RNA Dependent RNA Polymerase. 10.20944/preprints202003.0267.v1.

18. Anand, Kanchan & Yang, H. & Bartlam, Mark. (2005). Coronavirus main proteinase: Target for antiviral drug therapy. *Coronaviruses with Special Emphasis on First Insights Concerning*. 173-199.

19. Xue, Xiaoyu & Yu, Hongwei & Yang, Haitao & Xue, Fei & Wu, Zhixin & Shen, Wei & Li, Jun & Zhou, Zhe & Ding, Yi & Qi, Zhao & Zhang, Xuejun & Liao, Ming & Bartlam, Mark & Rao, Zihe. (2008). Structures of Two Coronavirus Main Proteinases: Implications for Substrate Binding and Antiviral Drug Design. *Journal of virology*. 82. 2515-27. 10.1128/JVI.02114-07.

20. Anand, Kanchan & Ziebuhr, John & Wadhwani, Parvesh & Mesters, Jeroen & Hilgenfeld, Rolf. (2003). Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs. *Science (New York, N.Y.)*. 300. 1763-7. 10.1126/science.1085658.

21. Gao, Yan & Liming, Yan & Huang, Yucen & Liu, Fengjiang & Zhao, Yao & Cao, Lin & Wang, Tao & Sun, Qianqian & Ming, Zhenhua & Zhang, Lianqi & Ge, Ji & Zheng, Litao & Zhang, Ying & Wang, Haofeng & Zhu, Yan & Zhu, Chen & Hu, Tianyu & Hua, Tian & Zhang, Bing & Rao, Zihe. (2020). Structure of the RNA-dependent RNA polymerase from COVID-19 virus. *Science*. 368. eabb7498. 10.1126/science.abb7498.

22. RCSB: <https://www.rcsb.org/structure/6M71>

23. Kirchdoerfer, R.N., Ward, A.B. Structure of the SARS-CoV nsp12 polymerase bound to nsp7 and nsp8 co-factors. *Nat Commun* 10, 2342 (2019). <https://doi.org/10.1038/s41467-019-10280-3>

24. Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B. A., Thiessen, P. A., Yu, B., Zaslavsky, L., Zhang, J., & Bolton, E. E. (2019). PubChem 2019 update: improved access to chemical data. *Nucleic acids research*, 47(D1), D1102–D1109. <https://doi.org/10.1093/nar/gky1033>

25. Crotty, Shane & Maag, David & Arnold, Jamie & Zhong, WD & Lau, Johnson & Hong, Zhi & Andino, Raul & Cameron, Craig. (2001). The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. *Nature medicine*. 6. 1375-9. 10.1038/82191.

26. Powdrill, Megan & Bernatchez, Jean & Götte, Matthias. (2010). Inhibitors of the hepatitis C virus RNA-dependent RNA polymerase NS5B. *Viruses*. 2. 2169-95. 10.3390/v2102169.
27. Lawitz, Eric & Buti, Maria & Vierling, John & Almasio, Piero & Bruno, Savino & Ruane, Peter & Hassanein, Tarek & Müllhaupt, Beat & Pearlman, Brian & Jancoriene, Ligita & Gao, Wei & Huang, Hsueh-Cheng & Shepherd, Aimee & Tannenbaum, Brynne & Fernsler, Doreen & Li, Jerry & Grandhi, Anjana & Liu, Hong & Su, Feng-Hsiu & Yoshida, Eric. (2017). Safety and efficacy of a fixed-dose combination regimen of grazoprevir, ruzasvir, and uprifosbuvir with or without ribavirin in participants with and without cirrhosis with chronic hepatitis C virus genotype 1, 2, or 3 infection (C-CREST-1 and C-CREST-2, part B): two randomised, phase 2, open-label trials. *The Lancet Gastroenterology & Hepatology*. 2. 10.1016/S2468-1253(17)30163-2.
28. Takehara, T., Chayama, K., Kurosaki, M. et al. JNJ-4178 (adafosbuvir, odalasvir, and simeprevir) in Japanese patients with chronic hepatitis C virus genotype 1 or 2 infection with or without compensated cirrhosis: the Phase IIa OMEGA-3 study. *J Gastroenterol* 55, 640–652 (2020). <https://doi.org/10.1007/s00535-020-01672-0>
29. Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S. and Olson, A. J. (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. *J. Computational Chemistry* 2009, 16: 2785-91.
30. O. Trott, A. J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading, *Journal of Computational Chemistry* 31 (2010) 455-461
31. Dallakyan S, Olson AJ., Small-Molecule Library Screening by Docking with PyRx. *Methods Mol Biol*. 2015;1263:243-50.
32. Hwang, William & Lin, Yaqiong & Santelli, Eugenio & Sui, Jianhua & Jaroszewski, Lukasz & Stec, Boguslaw & Farzan, Michael & Marasco, Wayne & Liddington, Robert. (2006). Structural Basis of Neutralization by a Human Anti-severe Acute Respiratory Syndrome Spike Protein Antibody, 80R. *The Journal of biological chemistry*. 281. 34610-6. 10.1074/jbc.M603275200.
33. Gui, Miao & Song, Wenfei & Zhou, Haixia & xu, Jingwei & Chen, Silian & Xiang, Ye & Wang, Xinquan. (2016). Cryo-electron microscopy structures of the SARS-CoV spike glycoprotein reveal a prerequisite conformational state for receptor binding. *Cell research*. 27. 10.1038/cr.2016.152.
34. Cho, Aesop & Zhang, Lijun & Xu, Jie & lee, rick & Butler, Thomas & Metobo, Sammy & Aktoudianakis, Vangelis & Lew, Willard & Ye, Hong & Clarke, Michael & Doerffler, Edward & Byun, Daniel & Wang, Ting & Babusis, Darius & Carey, Anne & German, Polina & Sauer, Dorothea & Zhong, Weidong & Rossi, Stephen & Kim, Choung. (2013). Discovery of the First C-Nucleoside HCV Polymerase Inhibitor (GS-6620) with Demonstrated Antiviral Response in HCV Infected Patients. *Journal of medicinal chemistry*. 57. 10.1021/jm400201a.
35. USPATENT: <https://pubchem.ncbi.nlm.nih.gov/patent/US2019046552>
36. Laskowski R A, Swindells M B (2011). LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. *J. Chem. Inf. Model.*, 51, 2778-2786. [PubMed id: 21919503]

37. Wallace A C, Laskowski R A, Thornton J M (1996). LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. *Protein Eng.*, 8, 127-134. [PubMed id: 7630882]
38. Kim, Chang & Chang, Kyong-Mi. (2013). Hepatitis C virus: Virology and life cycle. *Clinical and molecular hepatology*. 19. 17-25. 10.3350/cmh.2013.19.1.17.
39. CID 5064; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/5064>
40. CID 37542; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/37542>
41. CID 100252 ; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/100252>
42. CID 122108; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/122108>
43. CID 124970; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/124970>
44. CID 129235; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/129235>
45. CID 362949; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/362949>
46. CID 451448; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/451448>
47. CID 451949; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/451949>
48. CID 452722; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/452722>
49. CID 460516; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/460516>
50. CID 6713992; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/6713992>
51. CID 10220469; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/10220469>
52. CID 11436477; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/11436477>
53. CID 40629571; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/40629571>
54. CID 54759694; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/54759694>
55. CID 70989848; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/70989848>
56. CID 76325303; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/76325303>
57. CID 90055716; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/90055716>
58. CID 118596336; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/118596336>
59. CID 121304016; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/121304016>
60. CID 137465280; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/137465280>
61. CID 137490591; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/137490591>
62. CID 137490593; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/137490593>
63. CID 137509756; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/137509756>
64. CID 137517260; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/137517260>
65. CID 137517361; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/137517361>
66. CID 45375808; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/45375808>
67. CID 6440764; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/6440764>
68. CID 3652; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/3652>
69. CID 71826; URL: <https://pubchem.ncbi.nlm.nih.gov/compound/71826>

Abbreviations:

RdRP – RNA-dependent RNA polymerase; Cov 2 –Coronavirus 2; HCV - Hepatitis C Virus, NSP – Non structure Protein, SARS - Severe Acute Respiratory , MERS - Middle East Respiratory Syndrome, Cov - Coronavirus

Competing interests

The authors declare that they have no competing interests.

Consent for publication

Not applicable.

Ethics approval and consent to participate

Not applicable.

Funding

No funding.

Authors' contributions

Gudipati Pavan designed, coordinated this research, and drafted the manuscript. Shyamsri and Pankaj Drafted this manuscript and guided the work. The authors read and approved the final manuscript.